Vimpat is a medicine used on its own or as an add-on to other epilepsy medicines in the treatment of partial-onset seizures (epileptic fits starting in one specific part of the brain) with or without secondary generalisation (where the abnormal electrical activity spreads through the brain) in patients with epilepsy aged 2 years and older. Vimpat can also be used as add-on to other epilepsy medicines in the treatment of primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 4 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause). Vimpat contains the active substance lacosamide.
Therapeutic Indication
### Therapeutic indication Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Therapeutic Area (MeSH)
N/AATC Code
N03AX18
ATC Item
lacosamide
Pharmacotherapeutic Group
Antiepileptics
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| lacosamide | N/A | 拉考沙胺 |
EMA Name
Vimpat
Medicine Name
Vimpat
Aliases
N/ANo risk management plan link.
